Abstract

The goal of the current study was to identify potential roles of paraoxonase-2 in bladder carcinogenesis. T24 bladder cancer cells were transfected with plasmids inducing paraoxonase-2 silencing or overexpression. Upon the selection of clones stably down- or upregulating paraoxonase-2, cell proliferation, migration, and the production of reactive oxygen species were evaluated, before and after treatment with cisplatin and gemcitabine, used alone or in combination. The activity levels of both caspase-3 and caspase-8 were also analyzed. shRNA-mediated gene silencing and the overexpression of paraoxonase-2 revealed that the enzyme was able to promote both the proliferation and migration of T24 cells. Moreover, the knockdown of paraoxonase-2 was significantly associated with a reduced cell viability of T24 cells treated with chemotherapeutic drugs and led to both an increase of reactive oxygen species production and caspase-3 and caspase-8 activation. Conversely, under treatment with anti-neoplastic compounds, a higher proliferative capacity was found in T24 cells overexpressing paraoxonase-2 compared with controls. In addition, upon enzyme upregulation, both the production of reactive oxygen species and activation of caspase-3 and caspase-8 were reduced. Although further analyses will be required to fully understand the involvement of paraoxonase-2 in bladder tumorigenesis and in mechanisms leading to the development of chemoresistance, the data reported in this study seem to demonstrate that the enzyme could exert a great impact on tumor progression and susceptibility to chemotherapy, thus suggesting paraoxonase-2 as a novel and interesting molecular target for effective bladder cancer treatment.

Highlights

  • Bladder cancer (BC) is the ninth most common cancer in the world

  • Concerning bladder cancer, in our previous study, we demonstrated that the enzyme levels were significantly higher in tumors compared with adjacent normal looking tissue samples from BC patients

  • T24 cells transfected with pcDNA3-PON2 displayed a significant (p < 0.05) enzyme upregulation (2.49 ± 0.09) with respect to cells treated with pcDNA3 (1.20 ± 0.08) and the mock (1.00 ± 0.07) (Figure 1B)

Read more

Summary

Introduction

Bladder cancer (BC) is the ninth most common cancer in the world. The incidence of this neoplasm is gender-related, meaning that its frequency is 3-4 times higher in men than in women [1]. Smoking habits and exposure to some chemical compounds increase the risk of developing. Antioxidants 2020, 9, 175 often associated with the presence or future development of metastasis [2]. Concerning unresectable and metastatic forms, systemic chemotherapy is the standard initial treatment. Cisplatin or cisplatin-gemcitabine regimens have been the standard of care for many years [3]. Cisplatin-based chemotherapy is considered standard first-line treatment for patients with metastatic

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call